Home › Research › Drug development
Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis
Liu J, Wang LN.. Expert review of neurotherapeutics, 2019-05-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction : Alzheimer's disease (AD) is the most common phenotype of dementia. Mild cognitive impairment (MCI) due to AD is believed as a prodromal stage of AD. Intravenous immunoglobulin (IVIG) is a classical immunotherapy and potentially reduces AD-type pathology by anti-Aβ, anti-tau, anti-inflammatory effects, and non-antibody-mediated effects. Areas covered : The authors aimed to determine the efficacy and safety of IVIG for AD and MCI due to AD patients. The electronic databases including PubMed, EMBASE, CINAHL, Cochrane Library, and China National Knowledge Infrastructure were searched until March 2019. The results were pooled via a random-effects model. There were five eligible studies with 772 randomized patients with AD and MCI due to AD, which compared IVIG with placebo. Expert opinion : No significant differences were found in the scores of mini-mental state examination and Alzheimer's disease assessment scale-cognitive subscale and number of patients with adverse events. IVIG is well tolerated in the patients with AD and MCI due to AD, even in long-term therapy for 18 months. Insufficient evidences support IVIG in the treatment of patients with AD and MCI due to AD to improve cognition or disease modification. Well-designed randomized controlled trials with large sample sizes are required in the future.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, J., & Wang, L. N. (2019). Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis. Expert review of neurotherapeutics. https://doi.org/10.1080/14737175.2019.1620106
Vancouver
Liu J, Wang LN. Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis. Expert review of neurotherapeutics. 2019. doi:10.1080/14737175.2019.1620106. PMID: 31092051.
BibTeX
@article{liu2019-31092051,
author = {Liu, J. and Wang, L. N.},
title = {{Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis}},
journal = {Expert review of neurotherapeutics},
year = {2019},
doi = {10.1080/14737175.2019.1620106},
pmid = {31092051},
url = {https://doi.org/10.1080/14737175.2019.1620106}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The results were pooled via a random-effects model.
- Expert opinion : No significant differences were found in the scores of mini-mental state examination and Alzheimer's disease assessment scale-cognitive subscale and number of patients with adverse events.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 66/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 38 of the 58 points we could judge it on, which is 66 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert review of neurotherapeutics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31092051) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 38 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 38 of the 58 points we could judge it on is 66 out of 100. |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “intravenous”
2 studies in the library carry the topic tag “intravenous”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.